# Avoro Capital Advisors LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1633313. Source: https://holderbook.com/funds/1633313-avoro-capital-advisors-llc/

- Reported value: $11.1B
- Positions: 26
- Weight of the ten largest: 79.5%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $1.5B | 2,777,777 | 13.5% | 23 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $1.4B | 5,111,111 | 12.2% | 1 |
| KRYSTAL BIOTECH INC | [KRYS](https://holderbook.com/stocks/KRYS/) | $1.1B | 2,888,888 | 9.6% | 19 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $984.4M | 1,833,333 | 8.8% | 31 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $927.8M | 1,000,000 | 8.3% | 31 |
| ARROWHEAD PHARMACEUTICALS IN | [ARWR](https://holderbook.com/stocks/ARWR/) | $925.6M | 11,355,555 | 8.3% | 13 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $857.1M | 7,474,747 | 7.7% | 20 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $430.2M | 2,297,000 | 3.9% | 3 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $425.9M | 4,999,999 | 3.8% | 2 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $355.7M | 3,400,000 | 3.2% | 3 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $351.8M | 6,555,555 | 3.2% | 4 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $348.7M | 5,777,777 | 3.1% | 31 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $338.2M | 7,188,888 | 3.0% | 2 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $309.9M | 6,727,777 | 2.8% | 7 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $245.6M | 5,723,888 | 2.2% | 10 |
| TAYSHA GENE THERAPIES INC | [TSHA](https://holderbook.com/stocks/TSHA/) | $162.7M | 23,888,888 | 1.5% | 12 |
| OCULAR THERAPEUTIX INC | [OCUL](https://holderbook.com/stocks/OCUL/) | $123.1M | 12,540,000 | 1.1% | 10 |
| DAMORA THERAPEUTICS INC | [DMRA](https://holderbook.com/stocks/DMRA/) | $98.4M | 3,783,000 | 0.9% | 2 |
| HEMAB THERAPEUTICS HLDGS INC | - | $70.7M | 1,925,150 | 0.6% | 1 |
| GH RESEARCH PLC | [GHRS](https://holderbook.com/stocks/GHRS/) | $48.4M | 1,800,000 | 0.4% | 3 |
| VIRIDIAN THERAPEUTICS INC | [VRDN](https://holderbook.com/stocks/VRDN/) | $45.9M | 2,500,000 | 0.4% | 3 |
| SEPTERNA INC | [SEPN](https://holderbook.com/stocks/SEPN/) | $44.8M | 1,337,500 | 0.4% | 7 |
| AVALO THERAPEUTICS INC | [AVTX](https://holderbook.com/stocks/AVTX/) | $43.1M | 2,333,333 | 0.4% | 2 |
| FAETH THERAPEUTICS INC | [FTH](https://holderbook.com/stocks/FTH/) | $36.1M | 1,444,039 | 0.3% | 1 |
| WHITEHAWK THERAPEUTICS INC | [WHWK](https://holderbook.com/stocks/WHWK/) | $13.1M | 2,849,402 | 0.1% | 20 |
| LEXEO THERAPEUTICS INC | [LXEO](https://holderbook.com/stocks/LXEO/) | $6.9M | 1,489,189 | 0.1% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +20.4% | +14.8% | +5.6% | 87% |
| Q1 2026 | +4.5% | -4.6% | +9.1% | 95% |
| Q4 2025 | +24.7% | +2.4% | +22.4% | 95% |
| Q3 2025 | +34.0% | +7.8% | +26.2% | 100% |
| Q2 2025 | -0.8% | +10.5% | -11.3% | 100% |
| Q1 2025 | -7.3% | -4.6% | -2.7% | 100% |
| Q4 2024 | -2.5% | +2.1% | -4.6% | 100% |
| Q3 2024 | +2.6% | +5.4% | -2.8% | 96% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $11.1B | 26 |
| Q1 2026 | $10.2B | 30 |
| Q4 2025 | $10.2B | 33 |
| Q3 2025 | $7.7B | 30 |
| Q2 2025 | $5.7B | 30 |
| Q1 2025 | $6.4B | 33 |
| Q4 2024 | $7.1B | 39 |
| Q3 2024 | $6.9B | 36 |
| Q2 2024 | $7.5B | 41 |
| Q1 2024 | $8.6B | 46 |
| Q4 2023 | $7.2B | 42 |
| Q3 2023 | $6.4B | 46 |